All In Biotech

Drug Trial Radar · NCT07572123

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

A Two Cohort Randomized Study for Patients With High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

374

Planned (sponsor's estimate)

Start

Dec 4, 2026

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Sponsor type
NIH
First posted
May 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). In addition, the phase III trial will compare the effect of pembrolizumab after HDT-ASCT to standard of care HDT-ASCT alone in high-risk patients with relapsed or refractory classic Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. An ASCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving HDT before an ASCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Radiation therapy (RT) uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving brentuximab vedotin and nivolumab after radiation may be safe, tolerable and more effective than standard of care HDT-ASCT in treating patients with standard risk relapsed or refractory classic Hodgkin lymphoma. In addition, giving pembrolizumab after standard of care HDT-ASCT may be safe and tolerable and more effective than HDT-ASCT alone in treating high-risk patients with relapsed or refractory classic Hodgkin lymphoma.

Conditions

  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma

Interventions

  • 3-Dimensional Conformal Radiation TherapyRadiation

    Undergo 3DCRT

  • Autologous Hematopoietic Stem Cell TransplantationProcedure

    Undergo ASCT

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Brentuximab VedotinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT and PET/CT

  • High Dose ChemotherapyDrug

    Receive HDT

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo IMRT

  • NivolumabBiological

    Given IV

  • PembrolizumabBiological

    Given IV

  • Pencil Beam ScanningRadiation

    Undergo pencil beam proton RT

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Salvage TherapyProcedure

    Receive standard of care salvage therapy

  • Scattering Proton Beam TherapyRadiation

    Undergo passive scattering proton RT

  • TomotherapyRadiation

    Undergo tomotherapy

  • Uniform Active Scanning Proton Beam TherapyRadiation

    Undergo uniform scanning proton RT

  • Volume Modulated Arc TherapyRadiation

    Undergo VMAT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) (Standard risk cohort)Time frame: From randomization to progression or death without documented progression, assessed up to 15 years
  2. PFS (High-risk cohort)Time frame: From randomization to progression or death without documented progression, assessed up to 15 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.